Identification of Cysteine-Reactive Early Mitotic Inhibitors
5 affiliations
- 1Department of Chemistry and Biochemistry, University of California, Los Angeles, CA 90095.
- 2Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095.
- 3California NanoSystems Institute, University of California, Los Angeles, CA 90095.
- 4Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA 90095.
- 5Molecular Biology Institute, University of California, Los Angeles, CA 90095.
Abstract
Cancer remains a pervasive health problem for millions of Americans, and defining effective anticancer therapeutics remains a major obstacle to the long-term survival of patients. Recent advances in novel chemistries and chemical libraries have enabled researchers to discover and develop covalent inhibitors to treat various diseases, including cancer. This has spurred the generation of cysteine-targeting covalent compound libraries that have not been fully explored within the context of the cell cycle and cell division, which are attractive targets for inhibiting cancer proliferation. We report a novel, cell-based high-content chemical screening strategy for discovering early mitotic spindle assembly inhibitors. We coupled this strategy with a cysteine-reactive covalent compound library containing 3,520 molecules to identify novel early mitotic inhibitors. These inhibitors included a microtubule depolymerizer, a mitotic spindle positioning disruptor, and compounds affecting mitotic spindle structure and chromosome alignment. Two of these compounds triggered mitotic arrest and reduced cell viability at nanomolar concentrations. These inhibitors serve as chemical probes to investigate mechanisms of early cell division and to develop novel cancer therapeutics.
Related
- Isoforms of cysteine peptidases and osmotins instead of chitinases and peptidase inhibitors drive antifungal activity but occur as distinct isoforms in latex and callus tissues of Calotropis procera.
- Identification of a pan-orthoebolavirus-reactive antibody from an rVSV-EBOV vaccinated individual
- Identification of broadly tumour-reactive γδ TCRs from multiple myeloma
- Prime editing enables high-throughput identification and characterization of selective MutSβ inhibitors
- Phenolic Compounds from Ruta chalepensis Var. angustifolia as Potential HMG-CoA Reductase Inhibitors: Bioactivity-Guided Fractionation and Preliminary Identification of Active Metabolites
BibTeX
@misc{zhang2026identification,
title = {{Identification of Cysteine-Reactive Early Mitotic Inhibitors}},
author = {Xiaoxuan Zhang and Emma Buechler and Melissa Lopez and Mai Abdusamad and Cameron Taylor and Robert Damoiseaux and Jorge Z. Torres},
howpublished = {bioRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.13.758496},
url = {https://www.biorxiv.org/content/10.64898/2026.10.13.758496v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - Identification of Cysteine-Reactive Early Mitotic Inhibitors
AU - Xiaoxuan Zhang
AU - Emma Buechler
AU - Melissa Lopez
AU - Mai Abdusamad
AU - Cameron Taylor
AU - Robert Damoiseaux
AU - Jorge Z. Torres
PY - 2026
DA - 2026/10/13
PB - bioRxiv
DO - 10.64898/2026.10.13.758496
UR - https://www.biorxiv.org/content/10.64898/2026.10.13.758496v1
AB - Cancer remains a pervasive health problem for millions of Americans, and defining effective anticancer therapeutics remains a major obstacle to the long-term survival of patients. Recent advances in novel chemistries and chemical libraries have enabled researchers to discover and develop covalent inhibitors to treat various diseases, including cancer. This has spurred the generation of cysteine-targeting covalent compound libraries that have not been fully explored within the context of the cell cycle and cell division, which are attractive targets for inhibiting cancer proliferation. We report a novel, cell-based high-content chemical screening strategy for discovering early mitotic spindle assembly inhibitors. We coupled this strategy with a cysteine-reactive covalent compound library containing 3,520 molecules to identify novel early mitotic inhibitors. These inhibitors included a microtubule depolymerizer, a mitotic spindle positioning disruptor, and compounds affecting mitotic spindle structure and chromosome alignment. Two of these compounds triggered mitotic arrest and reduced cell viability at nanomolar concentrations. These inhibitors serve as chemical probes to investigate mechanisms of early cell division and to develop novel cancer therapeutics.
SN - 2692-8205
ER -